Communiqués Gilead Sciences, Inc. Buenos Aires S.E.

Actions

GILD

ARBCOM4601C4

Produits pharmaceutiques

Cours en clôture Buenos Aires S.E. 07/09/2026			Varia. 5j.	Varia. 1 janv.
60 300,00 ^ARS	+1,05%		+2,94%	+28,68%

19:50	Gilead Sciences inaugure un centre de recherche à son siège de Foster City	CI
03/09	Le traitement d'AbbVie contre le cancer du sang réduit la progression de la maladie et le risque de décès lors d'un essai clinique	RE

Communiqués

19:00	Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines	BU
28/08	Gilead Sciences : Breaks Ground on New Biologics Facility as Part of $32 Billion U.S. R&D and Manufacturing Investment	PU
27/08	U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens	BU
26/08	Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences	BU
24/08	European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status	BU
07/08	Gilead Sciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
05/08	Gilead Sciences : Second Quarter 2026 Summary of Remarks	PU
04/08	Gilead: Q2 Earnings Snapshot	AQ
04/08	CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results	BU
03/08	Gilead Sciences : Statement on California Supreme Court Decision in TDF Litigation	PU
29/07	South Africa's Next HIV Battle Isn't About Science, It's About Access	AQ
24/07	CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer	BU
24/07	AIDS 2026 - Gilead, Governments Must Make HIV Prevention Medicine More Accessible	AQ
23/07	Positive Interim Findings On New Once-Weekly HIV Treatment Pill	AQ
21/07	Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026	BU
21/07	Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure	BU
02/07	Gilead Sciences : Supports the PARTNERS Trial to Advance Research on Potential Treatments for Ebola Virus Disease	PU
24/06	U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer	BU
23/06	European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors	BU
16/06	U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention	AQ
15/06	U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention	BU
12/06	Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief	BU
11/06	National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership	BU
09/06	UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir	AQ
05/06	Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa	BU